The clinical benefit of ruxolitinib across patient subgroups: Analysis of a placebo-controlled, Phase III study in patients with myelofibrosis

Srdan Verstovsek, Ruben A Mesa, Jason R Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V. Catalano, Michael Werner Nikolaus Deininger, Carole B Miller, Richard T Silver, Moshe Talpaz, Elliott F Winton, Jimmie H Harvey, Murat O Arcasoy, Elizabeth Olson Hexner, Roger M Lyons, Ronald L Paquette, Azra Raza, Kris Vaddi, Susan Erickson-ViitanenWilliam Sun, Victor A Sandor, Hagop M Kantarjian

Research output: Contribution to journalArticleResearchpeer-review

62 Citations (Scopus)

Abstract

Myelofibrosis (MF) patients can present with a wide spectrum of disease characteristics. We analysed the consistency of ruxolitinib efficacy across patient subgroups in the COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment (COMFORT-I,) a double-blind trial, where patients with intermediate-2 or high-risk MF were randomized to twice-daily oral ruxolitinib (n=155) or placebo (n=154). Subgroups analysed included MF subtype (primary, post-polycythaemia vera, post-essential thrombocythaemia), age (≤65, >65years), International Prognostic Scoring System risk group, baseline Eastern Cooperative Oncology Group performance status (0, 1, ≥2), JAK2 V617F mutation (positive, negative), baseline haemoglobin level (≥100, <100g/l), baseline platelet count (100-200×109/l, >200×109/l), baseline palpable spleen size (≤10, >10cm), and baseline quartile of spleen volume and Total Symptom Score (TSS; Q1=lowest, Q4=highest). Mean percentage change from baseline to week 24 in spleen volume and TSS were calculated for ruxolitinib and placebo in each subgroup. Overall survival was estimated by Kaplan-Meier method according to original randomization group. In ruxolitinib-treated patients, reductions in spleen volume and TSS and evidence of improved survival relative to placebo across subgroups were consistent with those seen in the COMFORT-I population, confirming that ruxolitinib is an effective therapy for the spectrum of MF patients studied in COMFORT-I.

Original languageEnglish
Pages (from-to)508-516
Number of pages9
JournalBritish Journal of Haematology
Volume161
Issue number4
DOIs
Publication statusPublished - May 2013
Externally publishedYes

Keywords

  • Myelofibrosis
  • Ruxolitinib
  • Spleen volume
  • Subgroups
  • Symptoms

Cite this

Verstovsek, S., Mesa, R. A., Gotlib, J. R., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R. L., Raza, A., Vaddi, K., ... Kantarjian, H. M. (2013). The clinical benefit of ruxolitinib across patient subgroups: Analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. British Journal of Haematology, 161(4), 508-516. https://doi.org/10.1111/bjh.12274